Santen Pharmaceutical Co Stock Today
| SNPHY Stock | USD 11.00 0.01 0.09% |
Performance0 of 100
| Odds Of DistressLess than 44
|
Santen Pharmaceutical is trading at 11.00 as of the 29th of November 2024; that is 0.09% down since the beginning of the trading day. The stock's open price was 11.01. Santen Pharmaceutical has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Santen Pharmaceutical Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 388.22 M outstanding shares. More on Santen Pharmaceutical Co
Moving together with Santen Pink Sheet
| 0.83 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.87 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.77 | RHHBY | Roche Holding | PairCorr |
| 0.79 | RHHVF | Roche Holding AG | PairCorr |
Moving against Santen Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Santen Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Santen Pharmaceutical Co [SNPHY] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Santen Pharmaceutical's market, we take the total number of its shares issued and multiply it by Santen Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Santen Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 388.22 M outstanding shares.
Santen Pharmaceutical Co has accumulated about 69.53 B in cash with 46.04 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 176.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Santen Pharmaceutical Probability Of Bankruptcy
Ownership AllocationSanten Pharmaceutical shows a total of 388.22 Million outstanding shares. About 99.98 % of Santen Pharmaceutical outstanding shares are held by general public with 0.02 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Santen Ownership Details
Santen Pharmaceutical Risk Profiles
| Mean Deviation | 2.28 | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.79 | |||
| Risk Adjusted Performance | (0.03) |
Santen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Santen Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Santen Pharmaceutical Corporate Management
| Nobuko Kato | Chief Officer | Profile | |
| Mika Masunari | G Officer | Profile | |
| Nikolas Tripodis | Chief Officer | Profile | |
| Kaori Itagaki | Gen Group | Profile |
Additional Tools for Santen Pink Sheet Analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.